A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants
Status and phase
Completed
Phase 1
Conditions
Healthy
Treatments
Drug: D Amphetamine Matching Placebo
Drug: JNJ 54175446 Matching Placebo
Drug: JNJ-54175446
Drug: Minocycline
Drug: D Amphetamine
Study type
Interventional
Funder types
Industry
Identifiers
Details and patient eligibility
About
The purpose of this study is to investigate the safety, tolerability and pharmacodynamics of JNJ-54175446 after multiple consecutive dose administrations
Full description
This will be a randomized, placebo-and comparator-controlled, double-blind, multiple dose study with JNJ-54175446 in healthy male participants. The study will consist of a Screening examination (28 to 6 days prior to dose administration), a baseline 20 mg amphetamine (AMPH) challenge at least 5 days before first dose administration, a double-blind treatment period (18 days; 11 days of dosing with JNJ-54175446, minocycline or placebo; amphetamine (AMPH)/AMPH placebo challenge sequence on Day 7 and Day 10 for each participant), and a follow-up examination between 14 and 21 days after last dose administration. The maximal study duration for each participant will not exceed 9 weeks. Safety, pharmacokinetics (PK) and pharmacodynamics of JNJ-54175446 will be primarily assessed. Safety will be monitored throughout the study.
Enrollment
76 patients
Sex
Male
Ages
18 to 55 years old
Volunteers
Accepts Healthy Volunteers
Inclusion criteria
- Participant must have a body mass index (BMI) between 18 and 32 kilogram/meter^2 (kg/m^2), inclusive (BMI = weight/height^2)
- Participants must be healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) [including QTcF less than or equal to 450 millisecond (ms) (triplicate ECG)] performed at screening and admission to the clinical unit. Minor abnormalities in ECG, which are not considered to be of clinical significance by the investigator, are acceptable. The presence of Left Bundle Branch Block (LBBB), atrioventricular (AV) Block (second degree or higher), or a permanent pacemaker or implantable cardioverter defibrillator [ICD] will lead to exclusion
- Participants must be healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel [including liver enzymes], hematology, or urinalysis are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities to be not clinically significant. This determination must be recorded in the subject's source documents and initialed by the investigator
- A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug. In addition, their female partner should also use an appropriate method of birth control for at least the same duration
Exclusion criteria
- Participant has a history of or current liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances, any inflammatory illness or any other illness that the Investigator considers should exclude the subject
- Participant has a clinically significant (history of) psychiatric illnesses or (history of) psychotic symptoms
- Participant has a family history of relevant psychiatric disorders (first degree) and/or psychotic disorders (first and second degree)
- Participant has a history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HBsAg or anti-HCV at Screening
- Participant has a history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at Screening
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Parallel Assignment
Masking
Double Blind
76 participants in 8 patient groups
Cohort 1
Experimental group
Description:
Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
Treatment:
Drug: D Amphetamine
Drug: Minocycline
Drug: JNJ-54175446
Drug: JNJ 54175446 Matching Placebo
Drug: D Amphetamine Matching Placebo
Cohort 2
Experimental group
Description:
Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
Treatment:
Drug: D Amphetamine
Drug: Minocycline
Drug: JNJ-54175446
Drug: JNJ 54175446 Matching Placebo
Drug: D Amphetamine Matching Placebo
Cohort 3
Experimental group
Description:
Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
Treatment:
Drug: D Amphetamine
Drug: Minocycline
Drug: JNJ-54175446
Drug: JNJ 54175446 Matching Placebo
Drug: D Amphetamine Matching Placebo
Cohort 4
Experimental group
Description:
Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
Treatment:
Drug: D Amphetamine
Drug: Minocycline
Drug: JNJ-54175446
Drug: JNJ 54175446 Matching Placebo
Drug: D Amphetamine Matching Placebo
Cohort 5
Experimental group
Description:
Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
Treatment:
Drug: D Amphetamine
Drug: Minocycline
Drug: JNJ-54175446
Drug: JNJ 54175446 Matching Placebo
Drug: D Amphetamine Matching Placebo
Cohort 6
Experimental group
Description:
Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
Treatment:
Drug: D Amphetamine
Drug: Minocycline
Drug: JNJ-54175446
Drug: JNJ 54175446 Matching Placebo
Drug: D Amphetamine Matching Placebo
Cohort 7
Experimental group
Description:
Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
Treatment:
Drug: D Amphetamine
Drug: JNJ-54175446
Drug: JNJ 54175446 Matching Placebo
Drug: D Amphetamine Matching Placebo
Cohort 8
Experimental group
Description:
Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
Treatment:
Drug: D Amphetamine
Drug: JNJ-54175446
Drug: JNJ 54175446 Matching Placebo
Drug: D Amphetamine Matching Placebo
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems